Androgen Deprivation Therapy (ADT)ADT is a widely used treatment that reduces androgen levels, particularly testosterone, which fuels prostate cancer growth. Newer drugs like relugolix provide an oral alternative to traditional injections, improving convenience and patient outcomes.

Radioligand Therapy (RLT)A groundbreaking approach, radioligand therapy (such as Lutetium-177 PSMA) delivers targeted radiation to prostate cancer cells while sparing healthy tissue. This treatment has shown remarkable success in patients with advanced prostate cancer, significantly improving survival rates.

ImmunotherapyImmunotherapy enhances the body’s immune system to fight cancer. Sipuleucel-T, a personalized cancer vaccine, and checkpoint inhibitors like pembrolizumab help attack prostate cancer cells more effectively, especially in patients with specific genetic markers.

PARP InhibitorsPatients with BRCA1/2 or other DNA repair gene mutations benefit from PARP inhibitors like olaparib and rucaparib. These drugs exploit cancer cells’ inability to repair DNA damage, leading to their destruction and slowing cancer progression.

Androgen Receptor Degraders (SARDs)A newer class of drugs, selective androgen receptor degraders (SARDs), are proving effective against castration-resistant prostate cancer. Experimental treatments like bavdegalutamide show promise in overcoming resistance to traditional hormone therapies.

Focal TherapiesMinimally invasive treatments, such as high-intensity focused ultrasound (HIFU) and irreversible electroporation (IRE), target and destroy cancer cells without affecting surrounding tissues. These therapies offer fewer side effects compared to surgery or radiation.

Advanced Imaging and AI-Assisted DiagnosticsCutting-edge imaging techniques, like PSMA PET scans, allow for more precise cancer detection and treatment planning. AI-powered diagnostic tools are also enhancing early detection, leading to more successful treatment outcomes.